

OUR PIPELINE

LAST UPDATED: FEBRUARY 26, 2026

We are focused on revolutionizing medicine by developing product candidates for a range of severe diseases leveraging CRISPR expertise and other core technologies and therapeutic approaches.

PROGRAMS

| PROGRAM | INDICATION | RESEARCH AND PRECLINICAL | EARLY-STAGE CLINICAL | LATE-STAGE CLINICAL | PARTNERS |
|--|---|--------------------------|----------------------|---------------------|---------------------|
| Lonvo-z | Hereditary Angioedema (HAE) ¹ | | | | LEAD |
| Nex-z | Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) ² | | | | LEAD |
| Nex-z | Transthyretin Amyloidosis with Cardiomyopathy (ATTRv-CM) ² | | | | LEAD |
| REGV131-LNP1265 | Hemophilia B ³ | | | | |
| AVC-201 & AVC-203 | Acute Myeloid Leukemia (AML) & B-cell Malignancies ⁴ | | | | |
| Other Ongoing Research Programs | Various ⁵ | | | | |

Lead refers to lead development and commercial party.

1. Lonvo-z (lonvoguran ziclumeran), formerly referred to as NTLA-2002.
2. Nex-z (nexiguran ziclumeran), formerly referred to as NTLA-2001; Regeneron shares 25% of worldwide development costs and commercial profits for the ATTR program and has an option to enter into a co-promotion agreement for the U.S. commercialization.
3. Hemophilia B is being advanced solely by Regeneron; Intellia is eligible for milestones and royalties.
4. AVC-201 and AVC-203 are wholly owned by AvenCell and utilize proprietary allogeneic cell engineering technology licensed from Intellia.
5. Intellia is advancing both wholly owned and partnered programs.